Corporate and Scientific Advisory Board


Keith T. Flaherty, MD

Scientific Advisory Board Member

Dr Flaherty is Director of Clinical Research at the Cancer Center at Massachusetts General Hospital, where he was named as the Richard Saltonstall Endowed Chair in Oncology, and Professor of Medicine at Harvard Medical School. Dr. Flaherty's research focuses on the understanding of novel, molecularly targeted therapies in cancer and to define the mechanisms of action and resistance of novel therapies. A pioneer in developing targeted therapies matched to the genetic characteristics of a patient's tumor, Dr. Flaherty led early clinical trials on the development of vemurafenib and trametinib and the dabrafenib/trametinib combination. Dr. Flaherty serves as the Editor-in-Chief of Clinical Cancer Research and serves on the Board of Directors of the American Association for Cancer Research. He is also the Deputy Chair for Biomarker Sciences and the Chair of the Developmental Therapeutics Committee in the Eastern Cooperative Oncology Group, a Scientific Advisory Committee member for the Melanoma Research Foundation, and Past-President of the Society for Melanoma Research.  Dr. Flaherty is a founding member of X4 Pharmaceuticals, former Director and Chair of the SAB at Loxo Oncology, a wholly owned subsidiary of Eli Lilly and Co. Dr. Flaherty received his medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.

keith flaherty_edited.jpg

Jennifer Petter, PhD

Scientific Advisory Board Member

Dr. Petter is the founding CEO and current CSO of Arrakis Therapeutics. Previously, Jennifer was Vice President of Drug Discovery at Avila Therapeutics and, after the acquisition of Avila by Celgene in 2012, she became Celgene’s Vice President of Chemistry, a position she held until leaving to found Arrakis in 2015. Prior to Avila, Jennifer served as Vice President of Research at Mersana Therapeutics, Director of Small Molecule Drug Discovery at Biogen and as Section Head in Oncology Chemistry at Sandoz/Novartis. Prior to her career in industry, Jennifer was an Assistant Professor of Chemistry at the University of Pittsburgh. Jennifer holds an A.B. in chemistry from Dartmouth College and earned her PhD in organic chemistry at Duke University with Ned Porter. She was a post-doctoral fellow in Ron Breslow’s group at Columbia University.


Nahum Sonenberg, PhD

Scientific Advisory Board Member

Dr. Sonenberg is world-renowned as a leading expert in translational control mechanisms, making seminal contributions to our understanding of translation, and notably for the discovery of the mRNA 5' cap-binding protein, eIF4E, the rate-limiting component of the eukaryotic translation apparatus.  He is a recipient of the Robert L. Nobel Prize of the National Cancer Institute of Canada, the Killiam Prize for Health Sciences, the Gairdner Foundation International Award, the Rosenstiel Award and the Wolf Prize in Medicine, among many others.  Dr. Sonenberg is a Professor and Gilman Cheney Chair in the Department of Biochemistry at McGill University and Principal Investigator at the Rosalind and Morris Goodman Cancer Center.


Yat Sun Or, PhD

Scientific Advisory Board Member

Dr. Or is Chief Scientific Officer of Enanta Pharmaceuticals, and has led the Research and Development team since late 1999, which has discovered and developed numerous drugs and established a substantial IP estate.  Prior to that, he held key leadership positions at Abbott Laboratories from 1985 to 1999, where he received two Chairman’s Awards for outstanding research. Preceding Abbott, Dr. Or was a member of the cardiovascular drug discovery team at Schering-Plough. Dr. Or received his PhD in Organic Chemistry from the University of Chicago and completed Postdoctoral Fellowships at Ohio State University and Indiana University.


Jan van Heek, MBA

Corporate Advisory Board Member

Mr. van Heek is currently a board member of Amarin Corporation, and Minerva Neurosciences, both publicly traded biopharmaceutical companies. Since 2009, Mr. van Heek has been a Principal and Partner at BioPoint Group, a business development consulting company. Prior to establishing BioPoint in 2009, Mr. van Heek spent more than 18 years at Genzyme Corporation, a Sanofi pharmaceutical company, most recently as Executive Vice President and Senior Advisor to the chief executive officer and senior management team. He was also a board member and Chairman of the Audit Committee of ViaCell Corporation, a public company, from 2002 until it was sold to Perkin Elmer Corporation in 2007. He received an MBA from St. Gallen University in Switzerland and an executive degree from Stanford Business School.


Gerhard Wagner, PhD

Scientific Co-Founder, Director

Dr. Wagner is the Scientific Co-Founder of PIC Therapeutics and is world-renowned as a leading expert in NMR spectroscopy.  During his tenure at the University of Michigan in Ann Arbor, he developed triple-resonance methods and the procedures for studies of protein dynamics. Since 1990, Dr. Wagner has been a Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.  His research focuses on eukaryotic translation initiation, transcriptional activation and membrane proteins in micelles and nanodiscs.  A particular focus of his research is on discovery and characterization of small molecule inhibitors of protein-protein interactions.  He has been elected to the German National Academy of Sciences (Leopoldina), The National Academy of Science USA and the American Academy of Arts and Sciences. Dr. Wagner obtained his PhD from the ETH Zürich in 1977 with NMR studies of protein dynamics.